Health AI Central
Peer-Reviewed Publication
Brachytherapy2026June 1, 2026Letter

Response to the "Letter to the editor with regards to 'A biologically effective dose-based framework for integrating LDR brachytherapy and EBRT in glioblastoma treatment' by Turner et al." from Dr. Christopher J. Tien and Dr. Zhe (Jay) Chen.

Adam C Turner1, Elliot M Abbott2, Michael A Garcia3, David G Brachman3
1Department of Medical Affairs, GT Medical Technologies, Inc., Tempe, Arizona, United States of America. Electronic address: aturner@gammatile.com.
2Department of Clinical Science, MIM Software, A GE HealthCare Company, Cleveland, Ohio, United States of America.
3Department of Medical Affairs, GT Medical Technologies, Inc., Tempe, Arizona, United States of America.
PubMed DOI

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.